Back to top
more

Pediatrix Medical Group, Inc. (MD)

(Real Time Quote from BATS)

$15.90 USD

15.90
152,901

+0.25 (1.60%)

Updated Dec 8, 2022 02:09 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.51%
2Buy17.96%
3Hold9.47%
4Sell5.16%
5Strong Sell2.21%
S&P50010.66%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 45% (137 out of 250)

Industry: Medical Services

Trades from $1

Zacks News

Pediatrix (MD) Down 19% Since Q3 Earnings & Revenue Miss

Pediatrix's (MD) Q3 results reflect volume constraints and an elevated expense level. Adjusted EBITDA is now expected within $240-$245 million, down from the earlier view of $260-$270 million.

Pediatrix Medical Group (MD) Misses Q3 Earnings and Revenue Estimates

Pediatrix Medical Group (MD) delivered earnings and revenue surprises of -24.53% and 4.50%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Can Humana (HUM) Sustain Its Earnings Beat Streak in Q3?

Humana's (HUM) Q3 results are expected to reflect growing premiums, attributable to its Medicare Advantage and Medicaid businesses. However, elevated marketing costs might have strained its margins.

NovoCure (NVCR) Reports Q3 Loss, Lags Revenue Estimates

NovoCure (NVCR) delivered earnings and revenue surprises of 16.67% and 2.85%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Kaibalya Pravo Dey headshot

3 Healthcare Stocks Set to Outshine Q3 Earnings Estimates

Recovering volumes, improved admissions, growing health awareness and wide utilization of technologies in the third quarter are expected to have aided healthcare stocks like Humana (HUM), Teladoc (TDOC) and Pediatrix Medical (MD).

Can Rising Visits Help Teladoc (TDOC) Beat on Earnings in Q3?

The third-quarter results of Teladoc (TDOC) are likely to reflect a rise in Access Fees and Visit Fee revenues.

Earnings Preview: Avantor, Inc. (AVTR) Q3 Earnings Expected to Decline

Avantor, Inc. (AVTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pediatrix Medical Group (MD) to Report Q3 Results: Wall Street Expects Earnings Growth

Pediatrix Medical Group (MD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strength Seen in Icon PLC (ICLR): Can Its 5.3% Jump Turn into More Strength?

Icon PLC (ICLR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Elevance Health (ELV) to Post Q3 Earnings: A Beat in the Cards?

Elevance Health's (ELV) third-quarter results are likely to reflect improved premiums and net investment income.

Here's Why Pediatrix Medical Group (MD) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

MD or GDRX: Which Is the Better Value Stock Right Now?

MD vs. GDRX: Which Stock Is the Better Value Option?

The Beauty Health Company (SKIN) Stock Jumps 11.4%: Will It Continue to Soar?

The Beauty Health Company (SKIN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Pediatrix (MD) Up 8% Since Q2 Earnings Release, Revenues Up Y/Y

Pediatrix's (MD) second-quarter results reflect growth in patient volumes. Adjusted EBITDA is expected within $260-$270 million for 2022.

Mednax (MD) Q2 Earnings Match Estimates

Mednax (MD) delivered earnings and revenue surprises of 0% and 1.34%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Mednax (MD) Reports Next Week: Wall Street Expects Earnings Growth

Mednax (MD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Acadia Healthcare (ACHC) Tops Q2 Earnings and Revenue Estimates

Acadia Healthcare (ACHC) delivered earnings and revenue surprises of 9.09% and 0.71%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Industry Outlook Highlights Acadia Healthcare, Pediatrix Medical, Tenet Healthcare and Discover Financial Services

Acadia Healthcare, Pediatrix Medical, Tenet Healthcare and Discover Financial Services are part of Zacks Industry Outlook article.

Zacks.com featured highlights include Boot Barn, Canada Goose, Pediatrix Medical Group, Leap Therapeutics and Oncolytics Biotech

Boot Barn, Canada Goose, Pediatrix Medical Group, Leap Therapeutics, and Oncolytics Biotech are part of Zacks Screen of the week article.

Kaibalya Pravo Dey headshot

2 Top Hospital Stocks to Buy Despite Industry Headwinds

Rising supplies expense, wages and benefits, and other operating costs are lowering margins for the Zacks Medical-Hospital industry players. However, Acadia Healthcare and Pediatrix Medical are poised to win big with recovering patient volumes.

Sanghamitra Saha headshot

Ride on Rising P/E Investing With These 5 Top-Ranked Stocks

Want to try an out-of-the-box approach? Tap Oncolytics Biotech (ONCY), Pediatrix Medical Group Inc (MD), Boot Barn (BOOT), Canada Goose (GOOS) and Leap Therapeutics (LPTX).

Why Pediatrix Medical (MD) is a Solid Bet for Your Portfolio

Pediatrix Medical (MD) is expected to boost its services across maternal-fetal medicine, neonatology and obstetrics, plus 18 pediatric subspecialty offerings.

Will Mednax's (MD) New Name Pediatrix Medical be Beneficial?

Mednax's (MD) name change is expected to take effect following the closing bell on Jul 1, 2022.

    Why Acadia Healthcare (ACHC) Dips 1.6% Despite Q1 Earnings Beat

    Acadia Healthcare (ACHC) aims to add around 300 beds to its existing facilities in 2022.

    Mednax (MD) Down 20% Despite Q1 Earnings Beat on Patient Volumes

    Mednax (MD) continues to anticipate revenues of $2 billion and adjusted EBITDA of at least $270 million for 2022.